# Wendy Barclay

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4286022/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 166 papers | 15,799 citations | 28274 55 h-index | 26613 107 g-index |
| 247 all docs | 247 docs citations | 247 times ranked | 21256 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infectious Diseases, The, 2022, 22, 183-195. | 9.1 | 585 |
| 2 | SARS-CoV-2 environmental contamination from hospitalised patients with COVID-19 receiving aerosol-generating procedures. Thorax, 2022, 77, 259-267. | 5.6 | 34 |
| 3 | SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys. Lancet Respiratory Medicine,the, 2022, 10, 355-366. | 10.7 | 39 |
| 4 | SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell, 2022, 185, 467-484.e15. | 28.9 | 788 |
| 5 | Mutations that adapt SARS-CoV-2 to mink or ferret do not increase fitness in the human airway. Cell Reports, 2022, 38, 110344. | 6.4 | 46 |
| 6 | Multisystem screening reveals <scp>SARSâ€CoV</scp>â€2 in neurons of the myenteric plexus and in megakaryocytes. Journal of Pathology, 2022, 257, 198-217. | 4.5 | 16 |
| 7 | A common TMPRSS2 variant has a protective effect against severe COVID-19. Current Research in Translational Medicine, 2022, 70, 103333. | 1.8 | 30 |
| 8 | Rapid increase in Omicron infections in England during December 2021: REACT-1 study. Science, 2022, 375, 1406-1411. | 12.6 | 99 |
| 9 | Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection. Nature Immunology, 2022, 23, 40-49. | 14.5 | 145 |
| 10 | NaÃ¨ve Human Macrophages Are Refractory to SARS-CoV-2 Infection and Exhibit a Modest Inflammatory Response Early in Infection. Viruses, 2022, 14, 441. | 3.3 | 10 |
| 11 | Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nature Communications, 2022, 13, 907. | 12.8 | 94 |
| 12 | Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nature Medicine, 2022, 28, 1031-1041. | 30.7 | 281 |
| 13 | Ultrastructural insight into SARS-CoV-2 entry and budding in human airway epithelium. Nature Communications, 2022, 13, 1609. | 12.8 | 24 |
| 14 | The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. EBioMedicine, 2022, 77, 103902. | 6.1 | 23 |
| 15 | A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model. Vaccine, 2022, 40, 2848-2855. | 3.8 | 7 |
| 16 | SARS-CoV-2 variants of concern alpha, beta, gamma and delta have extended ACE2 receptor host ranges. Journal of General Virology, 2022, 103, . | 2.9 | 19 |
| 17 | Potent Virustatic Polymerâ€“Lipid Nanomimics Block Viral Entry and Inhibit Malaria Parasites In Vivo. ACS Central Science, 2022, 8, 1238-1257. | 11.3 | 9 |
| 18 | Breakthrough SARS-CoV-2 infections in double and triple vaccinated adults and single dose vaccine effectiveness among children in Autumn 2021 in England: REACT-1 study. EClinicalMedicine, 2022, 48, 101419. | 7.1 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Twin peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England. Science, 2022, 376, . | 12.6 | 78 |
| 20 | An early warning system for emerging SARS-CoV-2 variants. Nature Medicine, 2022, 28, 1110-1115. | 30.7 | 47 |
| 21 | Appropriately smoothing prevalence data to inform estimates of growth rate and reproduction number. Epidemics, 2022, 40, 100604. | 3.0 | 15 |
| 22 | Polymer formulated self-amplifying RNA vaccine is partially protective against influenza virus infection in ferrets. Oxford Open Immunology, 2022, 3, . | 2.8 | 2 |
| 23 | Robustness of the Ferret Model for Influenza Risk Assessment Studies: a Cross-Laboratory Exercise. MBio, 2022, 13, . | 4.1 | 12 |
| 24 | Machine learning to support visual auditing of home-based lateral flow immunoassay self-test results for SARS-CoV-2 antibodies. Communications Medicine, 2022, 2, . | 4.2 | 13 |
| 25 | Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2. Nature Microbiology, 2022, 7, 1180-1188. | 13.3 | 39 |
| 26 | Investigating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Surface and Air Contamination in an Acute Healthcare Setting During the Peak of the Coronavirus Disease 2019 (COVID-19) Pandemic in London. Clinical Infectious Diseases, 2021, 73, e1870-e1877. | 5.8 | 227 |
| 27 | Usability and Acceptability of Home-based Self-testing for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies for Population Surveillance. Clinical Infectious Diseases, 2021, 72, e384-e393. | 5.8 | 55 |
| 28 | SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. Nature Communications, 2021, 12, 905. | 12.8 | 168 |
| 29 | SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study. BMJ, The, 2021, 372, n423. | 6.0 | 56 |
| 30 | Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet, The, 2021, 397, 1178-1181. | 13.7 | 279 |
| 31 | The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Nature Microbiology, 2021, 6, 899-909. | 13.3 | 556 |
| 32 | Resurgence of SARS-CoV-2: Detection by community viral surveillance. Science, 2021, 372, 990-995. | 12.6 | 91 |
| 33 | Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia. Nature, 2021, 594, 88-93. | 27.8 | 293 |
| 34 | SARS-CoV-2 one year on: evidence for ongoing viral adaptation. Journal of General Virology, 2021, 102, . | 2.9 | 137 |
| 35 | Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults. Lancet Regional Health - Europe, The, 2021, 4, 100098. | 5.6 | 91 |
| 36 | Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model. PLoS Pathogens, 2021, 17, e1009527. | 4.7 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Favipiravir-resistant influenza A virus shows potential for transmission. PLoS Pathogens, 2021, 17, e1008937. | 4.7 | 23 |
| 38 | Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet, The, 2021, 398, 223-237. | 13.7 | 110 |
| 39 | The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells. Nature Communications, 2021, 12, 4068. | 12.8 | 57 |
| 40 | 2020 Hindsight: Should evolutionary virologists have expected the unexpected during a pandemic?. Evolution; International Journal of Organic Evolution, 2021, 75, 2311-2316. | 2.3 | 6 |
| 41 | Inactivation of SARS-CoV-2 in chlorinated swimming pool water. Water Research, 2021, 205, 117718. | 11.3 | 17 |
| 42 | A natural variant in ANP32B impairs influenza virus replication in human cells. Journal of General Virology, 2021, 102, . | 2.9 | 8 |
| 43 | The origins of SARS-CoV-2: A critical review. Cell, 2021, 184, 4848-4856. | 28.9 | 330 |
| 44 | SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature, 2021, 599, 114-119. | 27.8 | 1,041 |
| 45 | A prenylated dsRNA sensor protects against severe COVID-19. Science, 2021, 374, eabj3624. | 12.6 | 124 |
| 46 | Handheld Point-of-Care System for Rapid Detection of SARS-CoV-2 Extracted RNA in under 20 min. ACS Central Science, 2021, 7, 307-317. | 11.3 | 106 |
| 47 | Host Cell Factors That Interact with Influenza Virus Ribonucleoproteins. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a038307. | 6.2 | 14 |
| 48 | Acceptability, Usability, and Performance of Lateral Flow Immunoassay Tests for Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: REACT-2 Study of Self-Testing in Nonhealthcare Key Workers. Open Forum Infectious Diseases, 2021, 8, ofab496. | 0.9 | 12 |
| 49 | Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. Science, 2021, 374, eabl9551. | 12.6 | 111 |
| 50 | Amino acid substitutions in the H5N1 avian influenza haemagglutinin alter pH of fusion and receptor binding to promote a highly pathogenic phenotype in chickens. Journal of General Virology, 2021, 102, . | 2.9 | 2 |
| 51 | Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathogens, 2021, 17, e1010022. | 4.7 | 139 |
| 52 | Ultrastructure of cell trafficking pathways and coronavirus: how to recognise the wolf amongst the sheep. Journal of Pathology, 2020, 252, 346-357. | 4.5 | 13 |
| 53 | Host ANP32A mediates the assembly of the influenza virus replicase. Nature, 2020, 587, 638-643. | 27.8 | 89 |
| 54 | Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey. Thorax, 2020, 75, 1082-1088. | 5.6 | 133 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza. PLoS Pathogens, 2020, 16, e1008716. | 4.7 | 9 |
| 56 | Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study. Lancet Microbe, The, 2020, 1, e300-e307. | 7.3 | 92 |
| 57 | The Emergence of H7N7 Highly Pathogenic Avian Influenza Virus from Low Pathogenicity Avian Influenza Virus Using an in ovo Embryo Culture Model. Viruses, 2020, 12, 920. | 3.3 | 10 |
| 58 | Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe, The, 2020, 1, e245-e253. | 7.3 | 441 |
| 59 | Quantifying mechanistic traits of influenza viral dynamics using in vitro data. Epidemics, 2020, 33, 100406. | 3.0 | 10 |
| 60 | ACE2: The Only Thing That Matters?. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 161-163. | 5.6 | 4 |
| 61 | Population implications of the deployment of novel universal vaccines against epidemic and pandemic influenza. Journal of the Royal Society Interface, 2020, 17, 20190879. | 3.4 | 12 |
| 62 | Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nature Communications, 2020, 11, 3523. | 12.8 | 357 |
| 63 | Characterising viable virus from air exhaled by H1N1 influenza-infected ferrets reveals the importance of haemagglutinin stability for airborne infectivity. PLoS Pathogens, 2020, 16, e1008362. | 4.7 | 25 |
| 64 | Swine ANP32A Supports Avian Influenza Virus Polymerase. Journal of Virology, 2020, 94, . | 3.4 | 26 |
| 65 | Elucidating the Interactions between Influenza Virus Polymerase and Host Factor ANP32A. Journal of Virology, 2020, 94, . | 3.4 | 29 |
| 66 | Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission. PLoS Pathogens, 2020, 16, e1008395. | 4.7 | 28 |
| 67 | REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol. Wellcome Open Research, 2020, 5, 200. | 1.8 | 55 |
| 68 | Passage of influenza A/H3N2 viruses in human airway cells removes artefactual variants associated with neuraminidase-mediated binding. Journal of General Virology, 2020, 101, 456-466. | 2.9 | 9 |
| 69 | The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. Journal of General Virology, 2020, 101, 791-797. | 2.9 | 300 |
| 70 | REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol. Wellcome Open Research, 2020, 5, 200. | 1.8 | 93 |
| 71 | Title is missing!. , 2020, 16, e1008395. | | 0 |
| 72 | Title is missing!. , 2020, 16, e1008395. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Title is missing!. , 2020, 16, e1008395. | | 0 |
| 74 | Title is missing!. , 2020, 16, e1008395. | | 0 |
| 75 | Title is missing!. , 2020, 16, e1008716. | | 0 |
| 76 | Title is missing!. , 2020, 16, e1008716. | | 0 |
| 77 | Title is missing!. , 2020, 16, e1008716. | | 0 |
| 78 | Title is missing!. , 2020, 16, e1008716. | | 0 |
| 79 | Title is missing!. , 2020, 16, e1008716. | | 0 |
| 80 | Title is missing!. , 2020, 16, e1008716. | | 0 |
| 81 | Entry of the bat influenza H17N10 virus into mammalian cells is enabled by the MHC class II HLA-DR receptor. Nature Microbiology, 2019, 4, 2035-2038. | 13.3 | 35 |
| 82 | Host Determinants of Influenza RNA Synthesis. Annual Review of Virology, 2019, 6, 215-233. | 6.7 | 39 |
| 83 | Receptor for bat influenza virus uncovers potential risk to humans. Nature, 2019, 567, 35-36. | 27.8 | 6 |
| 84 | Pregnancy-related immune suppression leads to altered influenza vaccine recall responses. Clinical Immunology, 2019, 208, 108254. | 3.2 | 8 |
| 85 | ANP32 Proteins Are Essential for Influenza Virus Replication in Human Cells. Journal of Virology, 2019, 93, . | 3.4 | 68 |
| 86 | Effect of a Russian-backbone live-attenuated influenza vaccine with an updated pandemic H1N1 strain on shedding and immunogenicity among children in The Gambia: an open-label, observational, phase 4 study. Lancet Respiratory Medicine,the, 2019, 7, 665-676. | 10.7 | 34 |
| 87 | Regulation of influenza A virus mRNA splicing by CLK1. Antiviral Research, 2019, 168, 187-196. | 4.1 | 21 |
| 88 | Influenza Virus with Increased pH of Hemagglutinin Activation Has Improved Replication in Cell Culture but at the Cost of Infectivity in Human Airway Epithelium. Journal of Virology, 2019, 93, . | 3.4 | 25 |
| 89 | RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals. PLoS Pathogens, 2019, 15, e1007601. | 4.7 | 26 |
| 90 | Host and viral determinants of influenza A virus species specificity. Nature Reviews Microbiology, 2019, 17, 67-81. | 28.6 | 390 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Determining the Mutation Bias of Favipiravir in Influenza Virus Using Next-Generation Sequencing. Journal of Virology, 2019, 93, . | 3.4 | 42 |
| 92 | Species specific differences in use of ANP32 proteins by influenza A virus. ELife, 2019, 8, . | 6.0 | 68 |
| 93 | Urgent challenges in implementing live attenuated influenza vaccine. Lancet Infectious Diseases, The, 2018, 18, e25-e32. | 9.1 | 46 |
| 94 | The mechanism of resistance to favipiravir in influenza. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 11613-11618. | 7.1 | 243 |
| 95 | Ferrets as Models for Influenza Virus Transmission Studies and Pandemic Risk Assessments. Emerging Infectious Diseases, 2018, 24, 965-971. | 4.3 | 56 |
| 96 | Mouse Models of Influenza Infection with Circulating Strains to Test Seasonal Vaccine Efficacy. Frontiers in Immunology, 2018, 9, 126. | 4.8 | 46 |
| 97 | Assays to Measure the Activity of Influenza Virus Polymerase. Methods in Molecular Biology, 2018, 1836, 343-374. | 0.9 | 26 |
| 98 | Internal genes of a highly pathogenic H5N1 influenza virus determine high viral replication in myeloid cells and severe outcome of infection in mice. PLoS Pathogens, 2018, 14, e1006821. | 4.7 | 32 |
| 99 | Immune Escape Variants of H9N2 Influenza Viruses Containing Deletions at the Hemagglutinin Receptor Binding Site Retain Fitness In Vivo and Display Enhanced Zoonotic Characteristics. Journal of Virology, 2017, 91, . | 3.4 | 41 |
| 100 | Variability in H9N2 haemagglutinin receptor-binding preference and the pH of fusion. Emerging Microbes and Infections, 2017, 6, 1-7. | 6.5 | 46 |
| 101 | Can defective interfering RNAs affect the live attenuated influenza vaccine? â€“ Authors' reply. Lancet Infectious Diseases, The, 2017, 17, 1235-1236. | 9.1 | 3 |
| 102 | M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza. JCI Insight, 2017, 2, e91868. | 5.0 | 59 |
| 103 | Antiviral Screening of Multiple Compounds against Ebola Virus. Viruses, 2016, 8, 277. | 3.3 | 37 |
| 104 | Computational and molecular analysis of conserved influenza A virus RNA secondary structures involved in infectious virion production. RNA Biology, 2016, 13, 883-894. | 3.1 | 36 |
| 105 | Contact transmission of influenza virus between ferrets imposes a looser bottleneck than respiratory droplet transmission allowing propagation of antiviral resistance. Scientific Reports, 2016, 6, 29793. | 3.3 | 53 |
| 106 | Knowns and unknowns of influenza B viruses. Future Microbiology, 2016, 11, 119-135. | 2.0 | 88 |
| 107 | Species difference in ANP32A underlies influenza A virus polymerase host restriction. Nature, 2016, 529, 101-104. | 27.8 | 228 |
| 108 | NB protein does not affect influenza B virus replication in vitro and is not required for replication in or transmission between ferrets. Journal of General Virology, 2016, 97, 593-601. | 2.9 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | An engineered avian-origin influenza A virus for pancreatic ductal adenocarcinoma virotherapy. Journal of General Virology, 2016, 97, 2166-2179. | 2.9 | 9 |
| 110 | Influenza A virus PB1-F2 protein prolongs viral shedding in chickens lengthening the transmission window. Journal of General Virology, 2016, 97, 2516-2527. | 2.9 | 42 |
| 111 | Viral factors in influenza pandemic risk assessment. ELife, 2016, 5, . | 6.0 | 82 |
| 112 | The Functional Study of the N-Terminal Region of Influenza B Virus Nucleoprotein. PLoS ONE, 2015, 10, e0137802. | 2.5 | 9 |
| 113 | Oneâ€way trip: Influenza virus' adaptation to gallinaceous poultry may limit its pandemic potential. BioEssays, 2015, 37, 204-212. | 2.5 | 28 |
| 114 | Amino acid substitution D222N from fatal influenza infection affects receptor-binding properties of the influenza A(H1N1)pdm09 virus. Virology, 2015, 484, 15-21. | 2.4 | 10 |
| 115 | Ferret airway epithelial cell cultures support efficient replication of influenza B virus but not mumps virus. Journal of General Virology, 2015, 96, 2092-2098. | 2.9 | 5 |
| 116 | Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Research, 2015, 4, 30. | 1.6 | 57 |
| 117 | Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Research, 2015, 4, 30. | 1.6 | 63 |
| 118 | Low Dose Influenza Virus Challenge in the Ferret Leads to Increased Virus Shedding and Greater Sensitivity to Oseltamivir. PLoS ONE, 2014, 9, e94090. | 2.5 | 43 |
| 119 | Viral determinants of influenza A virus host range. Journal of General Virology, 2014, 95, 1193-1210. | 2.9 | 132 |
| 120 | Transfer of the Amino-Terminal Nuclear Envelope Targeting Domain of Human MX2 Converts MX1 into an HIV-1 Resistance Factor. Journal of Virology, 2014, 88, 9017-9026. | 3.4 | 87 |
| 121 | Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease. Mucosal Immunology, 2014, 7, 89-100. | 6.0 | 19 |
| 122 | Glycomic Characterization of Respiratory Tract Tissues of Ferrets. Journal of Biological Chemistry, 2014, 289, 28489-28504. | 3.4 | 82 |
| 123 | Accumulation of Human-Adapting Mutations during Circulation of A(H1N1)pdm09 Influenza Virus in Humans in the United Kingdom. Journal of Virology, 2014, 88, 13269-13283. | 3.4 | 84 |
| 124 | The Effect of the PB2 Mutation 627K on Highly Pathogenic H5N1 Avian Influenza Virus Is Dependent on the Virus Lineage. Journal of Virology, 2013, 87, 9983-9996. | 3.4 | 56 |
| 125 | Cellular immune correlates of protection against symptomatic pandemic influenza. Nature Medicine, 2013, 19, 1305-1312. | 30.7 | 757 |
| 126 | Investigation of Influenza Virus Polymerase Activity in Pig Cells. Journal of Virology, 2013, 87, 384-394. | 3.4 | 46 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Mutations in haemagglutinin that affect receptor binding and pH stability increase replication of a PR8 influenza virus with H5 HA in the upper respiratory tract of ferrets and may contribute to transmissibility. Journal of General Virology, 2013, 94, 1220-1229. | 2.9 | 58 |
| 128 | Transmission Studies Resume for Avian Flu. Science, 2013, 339, 520-521. | 12.6 | 34 |
| 129 | Unstable Polymerase-Nucleoprotein Interaction Is Not Responsible for Avian Influenza Virus Polymerase Restriction in Human Cells. Journal of Virology, 2013, 87, 1278-1284. | 3.4 | 41 |
| 130 | The Short Stalk Length of Highly Pathogenic Avian Influenza H5N1 Virus Neuraminidase Limits Transmission of Pandemic H1N1 Virus in Ferrets. Journal of Virology, 2013, 87, 10539-10551. | 3.4 | 72 |
| 131 | Pause on Avian Flu Transmission Research. Science, 2012, 335, 400-401. | 12.6 | 58 |
| 132 | Transmission of a 2009 H1N1 Pandemic Influenza Virus Occurs before Fever Is Detected, in the Ferret Model. PLoS ONE, 2012, 7, e43303. | 2.5 | 44 |
| 133 | Influenza Pandemics. Advances in Experimental Medicine and Biology, 2012, 719, 81-103. | 1.6 | 16 |
| 134 | An influenza reassortant with polymerase of pH1N1 and NS gene of H3N2 influenza A virus is attenuated in vivo. Journal of General Virology, 2012, 93, 998-1006. | 2.9 | 20 |
| 135 | Adjuvant-Free Immunization with Hemagglutinin-Fc Fusion Proteins as an Approach to Influenza Vaccines. Journal of Virology, 2011, 85, 3010-3014. | 3.4 | 47 |
| 136 | Receptor Binding Profiles of Avian Influenza Virus Hemagglutinin Subtypes on Human Cells as a Predictor of Pandemic Potential. Journal of Virology, 2011, 85, 1875-1880. | 3.4 | 46 |
| 137 | Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness. Journal of Antimicrobial Chemotherapy, 2011, 66, 466-470. | 3.0 | 61 |
| 138 | Lack of transmission of a human influenza virus with avian receptor specificity between ferrets is not due to decreased virus shedding but rather a lower infectivity in vivo. Journal of General Virology, 2011, 92, 1822-1831. | 2.9 | 45 |
| 139 | A Single Amino Acid in the HA of pH1N1 2009 Influenza Virus Affects Cell Tropism in Human Airway Epithelium, but Not Transmission in Ferrets. PLoS ONE, 2011, 6, e25755. | 2.5 | 28 |
| 140 | Evidence for Avian and Human Host Cell Factors That Affect the Activity of Influenza Virus Polymerase. Journal of Virology, 2010, 84, 9978-9986. | 3.4 | 88 |
| 141 | RIG-I Detects Viral Genomic RNA during Negative-Strand RNA Virus Infection. Cell, 2010, 140, 397-408. | 28.9 | 508 |
| 142 | Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs. Vaccine, 2010, 28, 2973-2979. | 3.8 | 9 |
| 143 | Avian Influenza Virus Glycoproteins Restrict Virus Replication and Spread through Human Airway Epithelium at Temperatures of the Proximal Airways. PLoS Pathogens, 2009, 5, e1000424. | 4.7 | 68 |
| 144 | A phase I clinical trial of a PER.C6Â® cell grown influenza H7 virus vaccine. Vaccine, 2009, 27, 1889-1897. | 3.8 | 136 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | A Complicated Message: Identification of a Novel PB1-Related Protein Translated from Influenza A Virus Segment 2 mRNA. Journal of Virology, 2009, 83, 8021-8031. | 3.4 | 318 |
| 146 | Mutations in H5N1 Influenza Virus Hemagglutinin that Confer Binding to Human Tracheal Airway Epithelium. PLoS ONE, 2009, 4, e7836. | 2.5 | 60 |
| 147 | The Development of a Reverse Genetics System Enabling the Rescue of Recombinant Avian Influenza Virus, A/turkey/england/50-92/91 (H5N1). Avian Diseases Digest, 2007, 2, e46-e46. | 0.0 | 2 |
| 148 | NS1 Proteins of Avian Influenza A Viruses Can Act as Antagonists of the Human Alpha/Beta Interferon Response. Journal of Virology, 2007, 81, 2318-2327. | 3.4 | 72 |
| 149 | Development of a Reverse Genetics System Enabling theRescue of Recombinant Avian Influenza Virus A/Turkey/England/50-92/91 (H5N1). Avian Diseases, 2007, 51, 393-395. | 1.0 | 19 |
| 150 | Alterations in Receptor Binding Properties of Recent Human Influenza H3N2 Viruses Are Associated with Reduced Natural Killer Cell Lysis of Infected Cells. Journal of Virology, 2007, 81, 11170-11178. | 3.4 | 52 |
| 151 | Probing the receptor interactions of an H5 avian influenza virus using a baculovirus expression system and functionalised poly(acrylic acid) ligands. Bioorganic and Medicinal Chemistry, 2007, 15, 4038-4047. | 3.0 | 13 |
| 152 | Generation of candidate human influenza vaccine strains in cell culture â€“ rehearsing the European response to an H7N1 pandemic threat. Influenza and Other Respiratory Viruses, 2007, 1, 157-166. | 3.4 | 28 |
| 153 | Infection of Human Airway Epithelium by Human and Avian Strains of Influenza A Virus. Journal of Virology, 2006, 80, 8060-8068. | 3.4 | 224 |
| 154 | Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host. Journal of Antimicrobial Chemotherapy, 2004, 53, 759-765. | 3.0 | 42 |
| 155 | Pandemic risks from bird flu. BMJ: British Medical Journal, 2004, 328, 238-239. | 2.3 | 15 |
| 156 | Restrictions to the Adaptation of Influenza A Virus H5 Hemagglutinin to the Human Host. Journal of Virology, 2004, 78, 502-507. | 3.4 | 61 |
| 157 | The M1 matrix protein controls the filamentous phenotype of influenza A virus. Virology, 2004, 321, 144-153. | 2.4 | 143 |
| 158 | Attenuating mutations in the influenza virus genome which may increase the safety of vaccine production. International Congress Series, 2004, 1263, 687-690. | 0.2 | 0 |
| 159 | A Reverse Genetics Approach for Recovery of Recombinant Influenza B Viruses Entirely from cDNA. Journal of Virology, 2002, 76, 11744-11747. | 3.4 | 67 |
| 160 | The time course of the humoral immune response to rhinovirus infection. Epidemiology and Infection, 1989, 103, 659-669. | 2.1 | 85 |
| 161 | A Common TMPRSS2 Variant Protects Against Severe COVID-19. SSRN Electronic Journal, 0, , . | 0.4 | 2 |
| 162 | Behavioural responses to SARS-CoV-2 antibody testing in England: REACT-2 study. Wellcome Open Research, 0, 6, 203. | 1.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Behavioural responses to SARS-CoV-2 antibody testing in England: REACT-2 study. Wellcome Open Research, 0, 6, 203. | 1.8 | 0 |
| 164 | Characterising the persistence of RT-PCR positivity and incidence in a community survey of SARS-CoV-2. Wellcome Open Research, 0, 7, 102. | 1.8 | 7 |
| 165 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study. Wellcome Open Research, 0, 6, 358. | 1.8 | 5 |
| 166 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study. Wellcome Open Research, 0, 6, 358. | 1.8 | 2 |